KYBELLA

Efficacy and Safety of Kybella When Used Off-Label

Kybella Off-Label Uses Investigated

Calvin T. Sung MD, et al, of the University of California, Riverside School of Medicine and University of California, Irvine, Department of Dermatology, performed a systematic literature search through PubMed, Cochrane, CINAHL and Web of Science databases, to investigate the safety and efficacy of injectable deoxycholic acid (DCA; Kybella; Allergan) when used off-label to treat fat tissue in areas of the body other than the submental region.

Allergan Completes Kythera Acquisition

Allergan has completed its acquisition of Kythera Biopharmaceuticals in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds KYBELLA (deoxycholic acid), the first FDA approved non-surgical injection for improvement in the appearance of moderate to severe submental fullness, to Allergan’s portfolio. In addition, Allergan also gains Kythera's development product setipiprant (KYTH-105), a novel compound for the prevention of androgenetic alopecia (AGA), or male pattern hair loss.

KYBELLA Injectable Approved for Double Chin

KYBELLA Injectable Approved for Double Chin

KYBELLA injection (deoxycholic acid, KYTHERA Biopharmaceutcials), also known as ATX-101, has been FDA approved for contouring moderate to severe convexity or fullness associated with submental fat in adults. KYBELLA is a nonhuman and non-animal formulation of deoxycholic acid that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, the drug destroys fat cells. The approval was based on the results of over 20 clinical studies involving more than 2,600 male and female patients.